Summarized by Masters of Longevity from Nature - Biotechnology.
Base editing’s decade-long journey from lab innovation to therapeutic development, explained in a concise review of scientific and clinical progress.
Key Takeaways
- Cytosine base editors were first described in 2016 and launched a shift toward precise chemical DNA correction.
- Base editors progressed into adenine editors and prime editors and became core platforms for therapeutic development.
- Base editing is now used in clinical trials for sickle cell disease, alpha-1 antitrypsin deficiency, PCSK9 hypercholesterolemia and leukemias.
